- Home
- DXR vs IFRX Comparison
DXR vs IFRX Comparison
Compare DXR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | IFRX |
|---|---|---|
| Founded | 1970 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.1M | 71.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | DXR | IFRX |
|---|---|---|
| Price | $14.25 | $1.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $25.00 | $8.50 |
| AVG Volume (30 Days) | 3.5K | ★ 658.1K |
| Earning Date | 02-27-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.46 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | $66,306.00 | ★ $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | $37.92 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.55 | $0.71 |
| 52 Week High | $14.76 | $2.77 |
Technical Indicators
Market Signals| Indicator | DXR | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.72 | 57.33 |
| Support Level | $13.20 | $0.99 |
| Resistance Level | $14.76 | $1.16 |
| Average True Range (ATR) | 0.59 | 0.08 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 86.45 | 89.13 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.